Tovuti hii inatekeleza vipengele vya msingi kwa sasa na bado haiko tayari kwa matumizi ya wagonjwa.
Tovuti hii inatekeleza vipengele vya msingi kwa sasa na bado haiko tayari kwa matumizi ya wagonjwa.
Chanjo ya majaribio dhidi ya virusi vya Zika vinavyoenezwa na mbu. Maambukizi kwa wajawazito husababisha microcephaly na kasoro nyingine za neva kwa fetasi. Hakuna chanjo iliyoidhinishwa kwa sasa.
Chanjo ya majaribio dhidi ya virusi vya Zika vinavyoenezwa na mbu. Maambukizi kwa wajawazito husababisha microcephaly na kasoro nyingine za neva kwa fetasi. Hakuna chanjo iliyoidhinishwa kwa sasa.
Hakuna chanjo iliyoidhinishwa kwa sasa. Chanjo zinazogombea ziko katika hatua za majaribio ya kimatibabu.
Investigational — specific contraindications will depend on the platform approved. General expectations: mRNA and inactivated candidates expected to have fewer contraindications. Any future live attenuated candidates would be contraindicated in pregnancy and immunocompromised. All candidates: severe allergy to components.
Investigational. Phase 1/2 data: VRC-ZKADNA090: injection site pain (~50%), fatigue, headache, myalgia — generally mild and self-limiting. mRNA-1893: injection site pain (56–78%), fatigue (30–40%), headache (25–35%), myalgia (20%). ZPIV: injection site pain (35%), fatigue, headache. No serious adverse events attributed to any candidate in published trials.
VRC-ZKADNA090 (DNA): 89% seroconversion, neutralizing titers ~1:100 (PRNT50). mRNA-1893: 94% seroconversion after 2 doses, higher GMT than DNA candidate. ZPIV: 92% seroconversion but requires alum adjuvant. No efficacy trials against clinical disease completed (low incidence post-2016 prevents traditional phase 3 trials — adaptive designs under consideration).
Investigational. Co-administration studies planned but limited data. Theoretical considerations: mRNA/inactivated platforms expected to be co-administrable with routine vaccines. Live attenuated: standard 28-day spacing with other live vaccines.
Key target population: women of childbearing age due to congenital Zika syndrome. mRNA and inactivated candidates expected to be safe in pregnancy (but no data yet). Live attenuated candidates: expected contraindication in pregnancy. Pre-conception vaccination strategy likely to be recommended.
No licensed vaccine available as of 2026. Prevention relies on mosquito avoidance (DEET, permethrin-treated clothing, bed nets), sexual transmission prevention (condoms for 3 months after travel for both sexes — CDC; conception timing: wait 3 months for men, 2 months for women after symptom onset/travel), and travel avoidance for pregnant women. WHO maintains Zika virus in R&D Blueprint priority list. Clinical development slowed post-2016 epidemic due to declining incidence making efficacy trials challenging.
Hakuna data ya ratiba inayopatikana.
Unajua chanjo unayohitaji? Vizuri. Hujui? Tuambie tu unaenda wapi — tutapata chanjo zinazofaa na kliniki. Bure, bila masharti.
Maudhui katika ukurasa huu ni kwa madhumuni ya habari na elimu pekee. Hayaundi ushauri wa kitabibu, utambuzi, au mapendekezo ya matibabu. Ikiwa una wasiwasi wa kiafya, wasiliana na mtaalamu wa afya aliyeidhinishwa. Medova si mtoa huduma za matibabu.
Masharti kamili ya matumizi